The European First Episode Schizophrenia Trial (EUFEST): Comparison of outcome in The European study of the effectiveness of haloperidol, amisulpride . The study helps solve the question of which category of antipsychotic medications best address impaired cognition, which affects a significant. The EUFEST study then undertook with a pragmatic open randomized-controlled trial design to compare the effectiveness of second-generation antipsychotic.
| Author: | Tobei Bakora |
| Country: | French Guiana |
| Language: | English (Spanish) |
| Genre: | Travel |
| Published (Last): | 24 May 2004 |
| Pages: | 132 |
| PDF File Size: | 16.16 Mb |
| ePub File Size: | 1.46 Mb |
| ISBN: | 925-8-95888-601-8 |
| Downloads: | 87343 |
| Price: | Free* [*Free Regsitration Required] |
| Uploader: | Kikinos |
The presence of one or more of the contra-indications against any of the study drugs. The primary outcome measure is retention in treatment, defined as time to discontinuation of study drug.
Results and Publications Publication and dissemination plan Not provided at time of registration Intention to publish date Participant level data Not provided at time of registration Basic results scientific Eeufest list 1. Study information Scientific title The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia Acronym EUFEST Study hypothesis What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of xtudy year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?
The aim of the European First Episode Schizophrenia Trial EUFEST is to compare treatment with amisulpride, quetiapine, olanzapine and ziprasidone to a low dose of haloperidol in an unselected sample of first episode schizophrenia patients with minimal prior exposure to antipsychotics.
These and other facts have stimulated discussions fufest the effectiveness of the new generation of antipsychotics. Loss of retention can be the result of insufficient clinical effect, or lack of tolerability or acceptance. Comparisons with haloperidol showed lower risks for any-cause discontinuation with amisulpride hazard ratio [HR] 0.
Result of results found for within. We focus on the real world treatment of first episode patients by enrolling heterogeneous patient populations, including patients who show comorbid drug abuse or who are aggressive or suicidal or less likely to be compliant with treatment.
Rationale and design of the trial. Ethics approval received from the local medical ethics committee. The Lancet ; What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients eufesr recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: Ethics approval Ethics approval received from the local medical ethics committee Study design Multicentre, randomised active controlled, parallel group trial Primary study design Interventional Secondary study design Randomised controlled trial Trial setting Hospitals Trial type Wufest Patient information sheet Condition Schizophrenia, schizophreniform, or schizoaffective disorder Intervention Drug: The study should be finished by the end of and it is expected that results will yield relevant clinical information with regard to the effectiveness of wufest second generation antipsychotics.
The presence of one or more of the contraindications against any of the study drugs. Retention to allocated study drug, which is the time that the patient stays on the randomised drug within the study dose range. The primary outcome measure was stusy treatment discontinuation. The principal investigators are Prof.
Genetic determinants of response to antipsychotic drugs 9. Secondary measures include changes in different dimensions of psychopathology, side effects, compliance, social needs, quality of life, substance abuse and cognitive functions.
The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.
Most studies comparing second generation antipsychotics with classical neuroleptics have been conducted in more or less chronic schizophrenia patients. Natural history of schizophrenia. Such studies were usually conducted in highly selected samples, and were generally designed and financed by the manufacturer of the drug tested. At present, more than patients have been recruited and randomized in the following countries: Comparison of outcome in first episode schizophrenia with different low syudy antipsychotic drug regimens.
Amisulpride, Haloperidol, Olanzapine, Quetiapine, Ziprasidone. Analysis was by intention to treat. Plain English Summary Not provided at time of registration Trial website http: Patients and their treating physicians were not blinded to the assigned treatment.
The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.
Psychopathology – positive symptoms, negative symptoms, depression, agitation-excitement, disorganisation 2. Schizophreniform or schizoaffective disorder; 3. Retention to allocated study drug, which is the time that the patient stays on the randomised drug within the study dose range. Second-generation antipsychotic drugs were introduced over a decade ago for the treatment of schizophrenia; however, their purported clinical effectiveness compared with first-generation antipsychotic drugs is still debated.
Side effects – extrapyramidal symptoms EPS side-effect profile, sexual side effects and weight gain 3. This outcome is assessed at regular time intervals until 12 months after recruitment. What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?
Intolerance to one of the drugs in this study 4. At regular time intervals patients are followed-up until 12 months after recruitment: We aimed to compare the effectiveness of second-generation antipsychotic drugs with that of a low dose of haloperidol, in first-episode schizophrenia.
Diagnosis of schizophrenia; 2. Quality of life 6. The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia. Diagnosis of schizophrenia, schizophreniform or schizoaffective disorder 2. Multicentre, randomised active controlled, parallel group trial.
We did an open randomised controlled trial of haloperidol atudy second-generation antipsychotic drugs in 50 sites, in 14 countries.
PfizerAstraZenecaSanofi-Aventis. EUFEST assesses the effectiveness of a low dose of haloperidol versus regular doses of 4 second generation antipsychotics: This pragmatic trial suggests that clinically meaningful antipsychotic treatment of first-episode of schizophrenia is achievable, for at least 1 year.